145 related articles for article (PubMed ID: 30324292)
1. Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries.
Singh P; Forman H; Adamson AS; Mostaghimi A; Ogdie AR; Oganisian A; Barbieri JS
J Gen Intern Med; 2019 Feb; 34(2):176-178. PubMed ID: 30324292
[No Abstract] [Full Text] [Related]
2. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
3. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.
Fleischman W; Agrawal S; Gross CP; Ross JS
J Gen Intern Med; 2019 Jul; 34(7):1074-1076. PubMed ID: 31011967
[No Abstract] [Full Text] [Related]
4. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
5. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.
Fleischman W; Agrawal S; King M; Venkatesh AK; Krumholz HM; McKee D; Brown D; Ross JS
BMJ; 2016 Aug; 354():i4189. PubMed ID: 27540015
[TBL] [Abstract][Full Text] [Related]
6. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
[TBL] [Abstract][Full Text] [Related]
7. Concentration of Opioid-Related Industry Payments in Opioid Crisis Areas.
Lee AJ; Bandari J; Macleod LC; Davies BJ; Jacobs BL
J Gen Intern Med; 2019 Feb; 34(2):187-189. PubMed ID: 30402818
[No Abstract] [Full Text] [Related]
8. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
[TBL] [Abstract][Full Text] [Related]
9. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries.
Mitchell AP; Winn AN; Dusetzina SB
JAMA Intern Med; 2018 Jun; 178(6):854-856. PubMed ID: 29630687
[TBL] [Abstract][Full Text] [Related]
11. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching.
Inoue K; Tsugawa Y; Mangione CM; Duru OK
PLoS Med; 2021 Jun; 18(6):e1003645. PubMed ID: 34061852
[TBL] [Abstract][Full Text] [Related]
12. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
13. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
Zezza MA; Bachhuber MA
PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
[TBL] [Abstract][Full Text] [Related]
14. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
15. [Diuretics and electrolytes].
Ritz E; Frey FJ
Ther Umsch; 2000 Jun; 57(6):343-4. PubMed ID: 10894016
[No Abstract] [Full Text] [Related]
16. Are Drugs Substitutes or Complements for Intensive (and Expensive) Medical Treatment.
Zhang Y; Newhouse JP; Baicker K
Am Econ Rev; 2011 May; 101(3):393-397. PubMed ID: 24058203
[No Abstract] [Full Text] [Related]
17. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
18. Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017.
Agarwal A; Roberts A; Dusetzina SB; Royce TJ
JAMA Oncol; 2020 Aug; 6(8):1271-1274. PubMed ID: 32469405
[TBL] [Abstract][Full Text] [Related]
19. Medicare Part D payments for neurologist-prescribed drugs.
De Lott LB; Burke JF; Kerber KA; Skolarus LE; Callaghan BC
Neurology; 2016 Apr; 86(16):1491-8. PubMed ID: 27009256
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors.
San-Juan-Rodriguez A; Prokopovich MV; Shrank WH; Good CB; Hernandez I
JAMA Intern Med; 2019 May; 179(5):713-716. PubMed ID: 30776053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
